Sudeep Pharma (SUDEEPPHRM) Share Price Falls 5% to Rs 1,275.85

Sudeep Pharma Share Price fell to Rs 1,275.85 on 09 September 2026, down 5% or Rs 67.10 from the previous close of Rs 1,342.95, taking the company’s market capitalisation to Rs 14,958.35 crore. The stock opened at Rs 1,367.25 and later slipped to an intraday low of Rs 1,275.85, while turnover stood at Rs 4.32 crore.

For investors searching Sudeep Pharma Share Price Today or Sudeep Pharma Stock News, the supplied data confirms the price move but does not establish any company-specific catalyst. That matters because the session was notable on price action alone: the stock opened above the previous close, never moved above the opening print, and was last quoted at the day’s low. At the same time, the company still trades at elevated valuation multiples and above-industry profitability ratios, which is why the move is drawing attention.

The immediate questions now are whether the stock stabilises after this decline, how its valuation compares with the Pharmaceuticals & Drugs benchmark, and whether its profitability profile continues to support premium pricing versus peers.

Sudeep Pharma (SUDEEPPHRM) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,275.85
Previous Close	Rs 1,342.95
Today's Move	-Rs 67.10 (-5%)
Open	Rs 1,367.25
High	Rs 1,367.25
Low	Rs 1,275.85
Turnover	Rs 4.32 crore
Market Capitalisation	Rs 14,958.35 crore
Market Cap Category	Mid Cap

Sudeep Pharma Share Price Today reflects a sharp one-session reset rather than a mild drift lower. The stock opened at Rs 1,367.25 against a previous close of Rs 1,342.95, indicating a stronger start to the session. However, the price failed to hold that level, and the day’s high remained the opening print itself. From there, the stock moved lower and touched Rs 1,275.85, which was also the current price at the time of the update.

That leaves the stock down Rs 67.10 or 5% on the day. The full intraday range between Rs 1,367.25 and Rs 1,275.85 was Rs 91.40, showing a wide swing and a weak closing position. Turnover of Rs 4.32 crore adds trading context. As a Mid Cap stock, Sudeep Pharma saw a meaningful decline that investors are likely to treat as a clear price event rather than ordinary day-to-day fluctuation.

Sudeep Pharma (SUDEEPPHRM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 14,958.35 crore
P/E Ratio	83.05x
P/B Ratio	16.42x
ROE	25.37%
ROCE	28.5%
EPS	Rs 16.17
Book Value Per Share	Rs 81.8
Dividend Yield	0.11%

Sudeep Pharma Fundamental Analysis shows a profitable business on the supplied ratios, but one that is also priced at a premium. The company’s market cap stands at Rs 14,958.35 crore, which is close to the industry average market capitalisation of Rs 14,150.82 crore and far above the same-industry median of Rs 715.60 crore. On valuation, the stock trades at a P/E ratio of 83.05 and a P/B ratio of 16.42.

Those figures are elevated relative to the Pharmaceuticals & Drugs benchmark, where the median P/E is 32.19 and the average is 49.13, while the median P/B is 3.05 and the average is 4.44. Even so, profitability metrics are stronger than the benchmark averages provided. Return on equity is 25.37% versus an industry median of 11.82% and average of 11.12%, while return on capital employed is 28.50% against a median of 13.71% and average of 13.62%.

EPS is Rs 16.17, book value per share is Rs 81.80, and dividend yield stands at 0.11%. Taken together, the supplied financials suggest investors are paying a rich multiple for above-benchmark return ratios, which helps explain why the stock’s decline is being watched closely.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	83.05x
Benchmark Median P/E	32.19x
Benchmark Average P/E	49.13x
Benchmark P/E Range	3.39x to 668.68x
Company P/B Ratio	16.42x
Benchmark Median P/B	3.05x
Benchmark Average P/B	4.44x
Company ROE	25.37%
Benchmark Median ROE	11.82%
Benchmark Average ROE	11.12%
Company ROCE	28.5%
Benchmark Median ROCE	13.71%
Benchmark Average ROCE	13.62%
Company Market Capitalisation	Rs 14,958.35 crore
Benchmark Median Market Cap	Rs 715.6 crore
Benchmark Average Market Cap	Rs 14,150.82 crore

Sudeep Pharma operates in the Healthcare sector and the Pharmaceuticals & Drugs industry, so the most relevant comparison is the supplied same-industry benchmark of 201 companies. On that basis, the stock’s valuation stands clearly above central industry levels, while its profitability metrics remain comfortably above both median and average benchmarks.

The benchmark data shows that the company’s P/E of 83.05 is above the industry median of 32.19 and average of 49.13. Within the peer set, P/E values range from 3.39 to 668.68 across 169 companies, so the stock sits in the higher-valued part of the pack without being at the extreme. Its P/B of 16.42 is also above the industry median of 3.05 and average of 4.44, against a range from -11.44 to 27 across 200 companies.

Profitability tells a different story. ROE at 25.37% is materially ahead of the industry median of 11.82% and average of 11.12%, while ROCE at 28.50% is also well above the median of 13.71% and average of 13.62%. In market-cap terms, the company is much larger than the industry median firm and broadly aligned with the industry average.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,55,825.66	37.31	5.22	14.85	19.11
Divi's Laboratories	DIVISLAB	2,47,018.51	86.86	14.38	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,86,874.73	86.55	21.03	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,15,211.69	25.42	4.25	19.69	21.39
Cipla	CIPLA	1,12,773	33.17	3.18	11.83	16

Sudeep Pharma’s peer comparison places it in a distinct position. Its market capitalisation of Rs 14,958.35 crore is far smaller than large listed pharmaceutical names such as Sun Pharmaceutical Industries at Rs 4,55,825.66 crore, Divi’s Laboratories at Rs 2,47,018.51 crore, Torrent Pharmaceuticals at Rs 1,86,874.73 crore, Zydus Lifesciences at Rs 1,15,211.69 crore and Cipla at Rs 1,12,773 crore. On size, it remains much smaller than the major listed peers in the supplied group.

On valuation, the company’s P/E of 83.05 is much higher than Sun Pharma at 37.31, Zydus at 25.42 and Cipla at 33.17, while sitting close to Divi’s at 86.86 and Torrent at 86.55. Its P/B of 16.42 is above Sun Pharma, Zydus and Cipla, above Divi’s 14.38, but below Torrent’s 21.03. Profitability is stronger than several large peers: ROE of 25.37% is ahead of Sun Pharma, Divi’s, Zydus and Cipla, though below Torrent’s 26.76%. ROCE of 28.50% is higher than Sun Pharma, Divi’s, Torrent, Zydus and Cipla. That suggests Sudeep Pharma Share Price is being valued more like a high-return pharma counter than a lower-multiple major.

Technical Snapshot

Beyond the day’s price move, the supplied technical indicators also add context. The RSI stands at 84.77, while the 50-day moving average is Rs 1,138.45 and the 200-day moving average is Rs 800.16. With the current price at Rs 1,275.85, the stock remains above both moving averages even after the day’s decline.

That does not explain why the stock fell during the session, and the supplied data should not be read as establishing a cause. It does, however, show that the latest drop is happening from levels still above both the 50 DMA and 200 DMA. For market watchers, that means the single-session weakness is occurring within a broader price structure that remains above these longer reference points.

Why Investors Are Watching Sudeep Pharma

• The stock fell 5% in a single session to Rs 1,275.85 from Rs 1,342.95.
• It opened at Rs 1,367.25, made the high at the open, and weakened to the day’s low.
• P/E of 83.05 and P/B of 16.42 are well above industry median and average levels.
• ROE of 25.37% and ROCE of 28.50% are both stronger than industry benchmark levels.
• The company’s Rs 14,958.35 crore market cap sits near the industry average but far below major pharma peers.
• Even after the decline, the stock remains above its 50 DMA of Rs 1,138.45 and 200 DMA of Rs 800.16.

About Sudeep Pharma

Sudeep Pharma is part of India’s Healthcare sector and is classified within the Pharmaceuticals & Drugs industry. Based on the supplied market context, the company operates in a segment that includes some of the country’s largest listed pharma businesses, but its own market capitalisation of Rs 14,958.35 crore is much smaller than the biggest diversified peers. That makes it relevant for investors who track mid-cap healthcare names with premium valuations and strong return ratios.

Track Sudeep Pharma Share Price on Univest

UseSudeep Pharma (SUDEEPPHRM) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

Investors tracking Sudeep Pharma Share Price can use Univest to follow live price moves, market cap trends, valuation ratios, profitability metrics and broader stock analysis in one place. Univest also helps users compare the stock with sector peers and review changes in price action without relying on scattered data points.

Frequently Asked Questions

Why did Sudeep Pharma Share Price fall today?

Ans. Sudeep Pharma Share Price fell 5% to Rs 1,275.85 from the previous close of Rs 1,342.95. The supplied data confirms the decline and intraday weakness, but it does not establish any company-specific reason for the move.

What is the current Sudeep Pharma share price today?

Ans. Sudeep Pharma share price today is Rs 1,275.85. At that level, the stock was down Rs 67.10, or 5%, from its previous close of Rs 1,342.95. The intraday range extended from Rs 1,275.85 to Rs 1,367.25.

How did Sudeep Pharma stock trade during the session?

Ans. The stock opened at Rs 1,367.25, which also became the day’s high, and later slipped to Rs 1,275.85, the day’s low. That pattern shows the session weakened steadily after the opening.

What is Sudeep Pharma’s market capitalisation?

Ans. Sudeep Pharma’s market capitalisation stands at Rs 14,958.35 crore. The supplied benchmark also shows this is above the Pharmaceuticals & Drugs industry median market cap of Rs 715.60 crore and close to the average of Rs 14,150.82 crore.

Is Sudeep Pharma expensive compared with its industry?

Ans. On the supplied benchmark, the company trades at a P/E of 83.05 versus the industry median of 32.19 and average of 49.13. Its P/B of 16.42 is also above the industry median of 3.05 and average of 4.44.

How profitable is Sudeep Pharma compared with the industry?

Ans. The company’s ROE is 25.37% and ROCE is 28.50%, both above the Pharmaceuticals & Drugs benchmark. Industry median ROE is 11.82% and median ROCE is 13.71%. The stock belongs to the Healthcare sector.

How does Sudeep Pharma compare with large pharma peers?

Ans. Sudeep Pharma is much smaller by market cap than Sun Pharma, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla. However, its ROCE of 28.50% is higher than each of those supplied peers in the comparison set.

Which sector and industry does Sudeep Pharma belong to?

Ans. Sudeep Pharma belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. That allows direct comparison with the supplied same-industry benchmark covering 201 companies. The stock belongs to the Healthcare sector.

What should investors monitor next in Sudeep Pharma Stock News?

Ans. Investors should monitor whether the stock stabilises after today’s 5% decline, and whether its premium P/E of 83.05 and P/B of 16.42 continue to be supported by ROE of 25.37% and ROCE of 28.50%.